Data on synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel NURR1/NOT agonist potentially useful for the treatment of Parkinson's disease

This article describes the chemical synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel Nurr1/NOT agonist. It is meant as a support to an article recently published in Bioorganic and Medicinal chemistry Letters and entitled “Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease” [1] and presenting the discovery, scope and potential of these new ligands of these nuclear receptors.